Search

Your search keyword '"rasopathy"' showing total 932 results

Search Constraints

Start Over You searched for: Descriptor "rasopathy" Remove constraint Descriptor: "rasopathy"
932 results on '"rasopathy"'

Search Results

1. Risk of Sudden Death in Patients With RASopathy Hypertrophic Cardiomyopathy

2. Clinical features and molecular genetics of patients with RASopathies: expanding the phenotype with rare genes and novel variants.

Catalog

Books, media, physical & digital resources

3. Recurrent p.H119Y variant in MAP2K1 expands the phenotypic spectrum of MAP2K1‐related RASopathy.

4. Case report: MEK inhibitor as treatment for multi-lineage mosaic KRAS G12D-associated epidermal nevus syndrome in a pediatric patient.

5. Noonan syndrome‐like phenotype associated with an ERF frameshift variant.

6. The ribosomal S6 kinase 2 (RSK2)–SPRED2 complex regulates the phosphorylation of RSK substrates and MAPK signaling

7. Combined HRAS and NRAS ablation induces a RASopathy phenotype in mice

8. A case of systemic lupus erythematosus in a patient with Noonan syndrome with recurrent severe hypoglycaemia.

9. Combined HRAS and NRAS ablation induces a RASopathy phenotype in mice.

10. Multiple central giant cell granuloma of the jaws: diagnostic signposts of Noonan syndrome and RASopathy.

25. Case report: MEK inhibitor as treatment for multi-lineage mosaic KRAS G12D-associated epidermal nevus syndrome in a pediatric patient

26. Obstetrical and neonatal outcomes of cardio-facio-cutaneous syndrome: Prenatal consequences of Ras/MAPK dysregulation.

27. Coronary arteriopathy in a patient with Noonan phenotype: Case report

28. Natural history and outcomes in paediatric RASopathy‐associated hypertrophic cardiomyopathy

29. Structural rearrangements as a recurrent pathogenic mechanism for SETBP1 haploinsufficiency

30. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.

32. Natural history and outcomes in paediatric RASopathy‐associated hypertrophic cardiomyopathy.

33. Structural rearrangements as a recurrent pathogenic mechanism for SETBP1 haploinsufficiency.

34. RAS isoform specific activities are disrupted by disease associated mutations during cell differentiation

37. The seventh international RASopathies symposium: Pathways to a cure—expanding knowledge, enhancing research, and therapeutic discovery

38. Long-term outcomes of surgery for obstructive hypertrophic cardiomyopathy in a pediatric cohortCentral MessagePerspective

39. Cross-species analysis of LZTR1 loss-of-function mutants demonstrates dependency to RIT1 orthologs.

40. Exome sequencing vs targeted gene panels for the evaluation of nonimmune hydrops fetalis

41. Molecular and phenotypic spectrum of cardio-facio-cutaneous syndrome in Chinese patients

42. Prenatal and infantile diagnosis of craniosynostosis in individuals with RASopathies.

43. The RRAS2 pathogenic variant (c.67G>T; p. Gly23Cys) produces Noonan syndrome with embryonal rhabdomyosarcoma.

44. Next generation sequencing aids diagnosis and management in a case of encephalocraniocutaneous lipomatosis.

45. Coronary arteriopathy in a patient with Noonan phenotype: Case report.

46. Structural insights into the role of SHOC2‐MRAS‐PP1C complex in RAF activation.

47. Phacomatosis spilosebacea: A new name for a distinctive binary genodermatosis.

48. Molecular and phenotypic spectrum of cardio-facio-cutaneous syndrome in Chinese patients.

49. Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Oncogenic EGFR.

50. The sixth international RASopathies symposium: Precision medicine-From promise to practice.